In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

226

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Chronic Liver Disease

Interventions

DRUG

LAENNEC (Human Placenta Hydrolysate) IV

Intravenous Injection

DRUG

LAENNEC (Human Placenta Hydrolysate) SC

Subcutaneous Injection

All Listed Sponsors

lead

Green Cross Wellbeing

INDUSTRY